Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

981
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
981
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

980
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
980
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

901
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
901
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Planar InAs avalanche photodiodes with high gain and low noise factor.

Optics express·2026
Same author

No One Left Behind: The Design of Young Biomedical Science Programme (YBMS) on Medical Education for Postdoctoral Fellows.

Medical science educator·2025
Same author

Cognitive frailty in older adults: examining the impact of frailty criteria on neuropsychological profile, functional outcomes, activity levels, and quality of life.

European geriatric medicine·2024
Same author

Fabrication of infrared linear arrays of InAs planar avalanche photodiodes.

Optics express·2022
Same author

Simulation of Al<sub>0.85</sub>Ga<sub>0.15</sub>As<sub>0.56</sub>Sb<sub>0.44</sub> avalanche photodiodes.

Optics express·2022
Same author

Cause-specific mortality in people with bullous pemphigoid and pemphigus vulgaris: a systematic review and meta-analysis.

The British journal of dermatology·2021
Same journal

Real-World Outcomes of Stapokibart-Based Combination Therapy for Bullous Pemphigoid: A Single-Center Retrospective Cohort.

Clinical and experimental dermatology·2026
Same journal

A second case of recessive mosaicism in ABCA12 causing a congenital unilateral epidermal nevus.

Clinical and experimental dermatology·2026
Same journal

Dermatopathology.

Clinical and experimental dermatology·2026
Same journal

Persistent Bilateral Palmar Hyperkeratotic Papules in an Adolescent Male.

Clinical and experimental dermatology·2026
Same journal

Shuddering Attacks in an Infant Treated with Atenolol for Infantile Hemangioma: A Previously Unreported Adverse Effect.

Clinical and experimental dermatology·2026
Same journal

Male genital fixed drug eruption: a systematic review.

Clinical and experimental dermatology·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Doxycycline-induced hypoglycaemia.

C H Tan1, C Shelley1, K E Harman1

  • 1Department of Dermatology, Leicester Royal Infirmary, Infirmary Square, Leicester, UK.

Clinical and Experimental Dermatology
|June 9, 2015
PubMed
Summary
This summary is machine-generated.

Doxycycline, a common antibiotic, can cause serious adverse reactions like hypoglycemia, even in patients without diabetes. This rare side effect highlights the need for careful monitoring during tetracycline treatment.

More Related Videos

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

5.1K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.7K

Related Experiment Videos

Last Updated: Apr 11, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

5.1K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.7K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Internal Medicine

Background:

  • Tetracyclines, including doxycycline, are frequently prescribed antibiotics.
  • Serious adverse reactions (SARs) to tetracyclines are uncommon.
  • Hypoglycemia is not a recognized complication of tetracycline therapy.

Observation:

  • An 80-year-old male patient with insulin-dependent diabetes was enrolled in a research study.
  • The patient developed unexpected hypoglycemia during doxycycline treatment.
  • This event represents a potential serious adverse reaction.

Findings:

  • Doxycycline treatment was associated with a serious adverse reaction of hypoglycemia.
  • The occurrence of hypoglycemia during tetracycline use is rare and not well-documented.
  • This case suggests a potential link between doxycycline and hypoglycemia.

Implications:

  • Clinicians should be aware of the potential for doxycycline-induced hypoglycemia, especially in vulnerable patients.
  • Further research is needed to determine the frequency and mechanisms of this rare adverse reaction.
  • Enhanced vigilance and monitoring may be necessary for patients on tetracycline therapy.